137
Participants
Start Date
February 9, 2012
Primary Completion Date
July 6, 2015
Study Completion Date
December 31, 2025
Sunitinib
50 mg PO daily for 28 days, q 6 weeks (1 cycle=6 weeks or 42 days)
Temsirolimus
25 mg IV weekly (Days 1, 8, 15, 22, 29, 36), q 6 weeks (1 cycle=6 weeks or 42 days)
Tom Baker Cancer Centre, Calgary
Cross Cancer Institute, Edmonton
BCCA - Cancer Centre for the Southern Interior, Kelowna
BCCA - Vancouver Cancer Centre, Vancouver
CancerCare Manitoba, Winnipeg
QEII Health Sciences Centre, Halifax
Izaak Walton Killam (IWK) Health Centre, Halifax
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton
London Regional Cancer Program, London
Ottawa Hospital Research Institute, Ottawa
Hospital for Sick Children, Toronto
Univ. Health Network-Princess Margaret Hospital, Toronto
CHUM - Hopital Notre-Dame, Montreal
McGill University - Dept. Oncology, Montreal
CHU Sainte-Justine, Montreal
Allan Blair Cancer Centre, Regina
Saskatoon Cancer Centre, Saskatoon
Collaborators (1)
Pfizer
INDUSTRY
Canadian Cancer Trials Group
NETWORK